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Abstract
Background: The homeobox gene TLX1 (for T-cell leukemia homeobox 1, previously known as HOX11) is inappropriately 
expressed in a major subgroup of T cell acute lymphoblastic leukemia (T-ALL) where it is strongly associated with 
activating NOTCH1 mutations. Despite the recognition that these genetic lesions cooperate in leukemogenesis, there 
have been no mechanistic studies addressing how TLX1 and NOTCH1 functionally interact to promote the leukemic 
phenotype.
Results: Global gene expression profiling after downregulation of TLX1 and inhibition of the NOTCH pathway in ALL-
SIL cells revealed that TLX1 synergistically regulated more than 60% of the NOTCH-responsive genes. Structure-
function analysis demonstrated that TLX1 binding to Groucho-related TLE corepressors was necessary for maximal 
transcriptional regulation of the NOTCH-responsive genes tested, implicating TLX1 modulation of the NOTCH-TLE 
regulatory network. Comparison of the dataset to publicly available biological databases indicated that the TLX1/
NOTCH-coregulated genes are frequently targeted by MYC. Gain- and loss-of-function experiments confirmed that 
MYC was an essential mediator of TLX1/NOTCH transcriptional output and growth promotion in ALL-SIL cells, with 
TLX1 contributing to the NOTCH-MYC regulatory axis by posttranscriptional enhancement of MYC protein levels. 
Functional classification of the TLX1/NOTCH-coregulated targets also showed enrichment for genes associated with 
other human cancers as well as those involved in developmental processes. In particular, we found that TLX1, NOTCH 
and MYC coregulate CD1B and RAG1, characteristic markers of early cortical thymocytes, and that concerted 
downregulation of the TLX1 and NOTCH pathways resulted in their irreversible repression.
Conclusions: We found that TLX1 and NOTCH synergistically regulate transcription in T-ALL, at least in part via the 
sharing of a TLE corepressor and by augmenting expression of MYC. We conclude that the TLX1/NOTCH/MYC network 
is a central determinant promoting the growth and survival of TLX1+ T-ALL cells. In addition, the TLX1/NOTCH/MYC 
transcriptional network coregulates genes involved in T cell development, such as CD1 and RAG family members, and 
therefore may prescribe the early cortical stage of differentiation arrest characteristic of the TLX1 subgroup of T-ALL.
Background
Homeodomain-containing transcription factors play a
major role in the establishment of metazoan body plans
and organogenesis. They are also involved in the mainte-
nance of tissue homeostasis, influencing the self-renewal
and differentiation of stem cells and their progenitors. A
number of experimental investigations have demon-
strated that homeodomain transcription factors regulate
multiple cellular functions including cell growth, prolifer-
ation, apoptosis, communication, adhesion and migration
[1,2]. It is not surprising therefore that anomalous expres-
sion of homeobox genes can disrupt developmental pro-
grams and contribute to neoplasia [3,4].
TLX1  is an evolutionarily conserved member of the
NKL (NK-Like or NK-Linked) subclass of Antennapedia
homeobox genes. During normal development, TLX1 is
required for the formation of the spleen and participates
in certain neuronal cell fate decisions [5-7]. Although
TLX1 is not normally expressed in the hematopoietic sys-
tem, its inappropriate expression due to chromosomal
translocations involving T cell receptor (TCR) genes is
associated with about 30% of adult and approximately 8%
of childhood T-cell acute lymphoblastic leukemia (T-
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ALL) cases [3,8]. T cell transforming activity of TLX1 has
been confirmed experimentally in studies of murine bone
marrow transplant recipients that received hematopoietic
stem cells expressing a retrovirally-delivered TLX1 trans-
gene [9,10]. However, a long latency of TLX1-induced
tumorigenesis indicated the necessity for additional
genetic abnormalities. In this regard, mutations activat-
ing NOTCH1 are observed in virtually all TLX1+ T-ALL
samples [11-13], arguing that the two factors frequently
cooperate in the neoplastic conversion of T cell progeni-
tors. NOTCH stimulates the PI3K-AKT-mTOR pathway
and transcriptionally activates the NF-κB, MYC and
HES1 transcription factors in T-ALL cells, but the critical
target genes responsible for the NOTCH1-induced
malignant phenotype remain to be fully defined [14-19].
The NOTCH receptor family plays an important role in
T cell development by providing instructional and
growth promoting signals [20,21]. Intrathymic T cell dif-
ferentiation is associated with sequential changes in the
expression of the CD1, CD3, CD4 and CD8 cell surface
markers [22,23]. Early thymocyte precursors do not
express CD3, CD4 or CD8. In-frame TCRβ rearrange-
ment and the generation of a functional pre-TCR com-
plex (TCRβ/pre-TCRα/CD3) at the cell surface allows
continued thymocyte development via the process of β-
selection. In humans, CD4 is transiently upregulated fol-
lowing β-selection and the immature single positive (ISP)
CD4+ cells rapidly give rise to CD4+CD8+ double positive
(DP) cells which undergo further maturation toward two
distinct populations represented by CD4+ or CD8+ single
positive (SP) phenotypes. NOTCH and/or pre-TCR sig-
naling provide survival and trophic functions until the
late DP stage when the cells become highly positive for
CD3 and depend on TCR signaling [24,25]. Specifically,
NOTCH signaling was shown to be obligatory for β-
selection [26], and the direct transcriptional target of
NOTCH, MYC, is a central integrator of NOTCH-medi-
ated survival [27,28] and preTCR-mediated proliferative
signals [29,30]. Surface expression of the CD1 family of
genes increases until the late DP stage, after which their
expression is extinguished and remains off in CD4+ and
CD8+ SP cells [31,32]. TLX1+ T-ALL samples exhibit a
predominantly CD1+CD3- surface phenotype with high
levels of TCR recombination activating gene (RAG1)
expression and TCRβ rearrangement on at least one
allele; but they often lack cytoplasmic and surface TCRβ
expression, suggesting that the onset of malignant trans-
formation occurs before β-selection [32-36]. However
TLX1+ leukemic cells are characteristically CD4+CD8+,
indicating that the oncogenic network allows the cells to
bypass the β-selection checkpoint and arrest at the early
cortical DP stage.
The direct transcriptional targets of NOTCH are
tightly regulated such that they are repressed in the
absence of a NOTCH activating signal [12,37]. In Droso-
phila, Groucho, a homolog of Transducin-like Enhancer-
of-split (TLE) proteins, directly associates with the Sup-
pressor of Hairless (the homolog of human RBP-Jκ)
repressor complex to block transcription from NOTCH-
responsive elements [38]. In mammals, SPEN/SHARP, a
different RBP-Jκ-associated corepressor protein performs
this function [39]. Instead, as was shown for the best
characterized target of NOTCH, HES1 (reviewed in [40]),
TLE proteins are involved in modulating NOTCH output
by a mechanism that involves autorepression of HES1 via
formation of a repressive HES1-TLE complex that recog-
nizes an N-box sequence in the HES1  promoter [41].
Moreover, the levels of HES1-repressive activity have
been shown to define the type of NOTCH response, e.g.,
whether it is repressed, oscillating or strongly activated
[42]. It is noteworthy that transcriptional repression in
response to NOTCH signaling occurs via an indirect
mechanism through downstream effectors; among these,
HES1-TLE repressor complexes play a central role, a well-
studied example of which is in the context of NOTCH
antineurogenic activity [43]. Thus, TLE corepressors con-
tribute to two aspects of NOTCH signaling: establishing
negative loops of regulation and mediating NOTCH
repressor activity. TLE proteins are also emerging as focal
points for crosstalk between signaling pathways [44,45].
Additionally, there is mounting evidence that the expres-
sion of TLE genes is altered in a growing list of human
cancers [46], including hematologic malignancies [41,47].
We recently showed that TLX1 interacts with TLE1 via
an Engrailed homology 1 (Eh1) motif (FXIXXIL, where X
can be any amino acid) encompassing amino acids 19-26
[46,48], and proposed that TLX1 activates transcription
a t  l e a s t  i n  p a r t  b y  d e r e p r e s s i n g  T L E - c o n t r o l l e d  g e n e s
[49]. Here we demonstrate that TLX1-TLE interaction
contributes in a positive manner to NOTCH transcrip-
tional programs in T-ALL. Functional classification of the
overlapping targets of these cooperating genetic lesions
showed enrichment for genes associated with other
human cancers as well as those involved in developmen-
tal processes. We found that TLX1 augments the
NOTCH-MYC regulatory axis by enhancing MYC pro-
tein levels and that this represents a major component of
TLX1-mediated growth control in ALL-SIL cells. We fur-
ther show that MYC coregulates a significant proportion
of common TLX1/NOTCH targets, among them the
CD1B and RAG1 genes characteristic of the early cortical
phenotype exhibited by TLX1+ T-ALLs [32-36]. Down-
regulation of TLX1 in concert with NOTCH blockade
resulted in irreversible repression of these genes. There-Riz et al. Molecular Cancer 2010, 9:181
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fore, our data suggest that the TLX1/TLE/NOTCH/MYC
network contributes to the pathogenesis of T-ALL by
concomitantly promoting the differentiation arrest and
expansion of cells at the CD1+ early cortical DP stage of
thymocyte development.
Results
TLX1 signature genes in T-ALL cells
In an effort to identify TLX1 target genes critical to the
malignant phenotype in T-ALL, we recently performed
gene expression profiling of a patient-derived TLX1+ T-
ALL cell line (ALL-SIL) where TLX1 was downregulated
by a lentiviral TLX1 shRNA knockdown approach [50].
Despite selection for vector-encoded drug resistance,
there was a certain degree of heterogeneity in TLX1 lev-
els within the transduced cells [50]. We therefore sought
to devise a strategy to obtain more homogeneous ALL-
SIL populations, ideally having more defined levels of
TLX1 expression. In that study, we observed that down-
regulation of TLX1 was associated with decreased levels
of CD1B and increased levels of CD55 at the mRNA level
and on the cell surface [50]. Based on those findings, we
used fluorescence-activated cell sorting (FACS) to isolate
the following ALL-SIL populations: cells with shRNA-
m e d i a t e d  k n o c k d o w n  o f  T L X 1  w e r e  s o r t e d  f o r  a
CD1bLowCD55High  surface phenotype (predicted "low"
TLX1), and control vector-transduced cells were sorted
into CD55High  (predicted intermediate or "medium"
TLX1) and CD55Low  (predicted "high" TLX1) popula-
tions. As anticipated, TLX1 protein levels in the resulting
populations exhibited an inverse correlation with surface
expression of CD55 (r = -0.9) (Figure 1A). We performed
expression profiling of the sorted TLX1High, TLX1Med and
TLX1Low  ALL-SIL cells to identify transcripts whose
changes in expression levels correlated with TLX1 pro-
tein levels. To globally validate and extend our previous
data, which was carried out using an Affymetrix oligonu-
cleotide microarray [50], we chose a 39,936 element
cDNA microarray for these experiments [51] (see ref.
[52]) (Additional file 1). The datasets of candidate TLX1-
responsive genes obtained using these two expression
platforms overlapped significantly (P < 0.0001), yielding a
robust consensus set of TLX1 signature genes (Figure 1B,
C).
To rule out off-target effects of the TLX1 shRNA, we
wanted to assess whether reintroduction of wild-type
TLX1 would reverse the knockdown impact on the
expression levels of representative genes selected from
the TLX1 signature gene list (see Figure 2B). In the exper-
iments described above, we downregulated endogenous
TLX1 using an shRNA (TLX1 shRNA95) directed against
the TLX1 coding region. To independently corroborate
target gene expression changes and to facilitate rescue
experiments by ectopic TLX1 expression, we used a dif-
ferent shRNA (TLX1 shRNA93) directed against the 3'
noncoding region of TLX1 mRNA. After lentiviral deliv-
ery of TLX1 shRNA93 and sorting for a
CD1bLowCD55High  surface profile, retroviral vectors
expressing the coding region of wild-type TLX1 (TLX1
WT) and two mutant TLX1 proteins were stably intro-
duced into the TLX1 knockdown cells (Figure 1D). As
shown in Figure 1E, regulation by TLX1 was confirmed
for the selected genes (DTX1, GAS1, HMGA2, L1TD1,
PLAC8, SH3BP5, SLC44A1) (P < 0.05, TLX1 WT vs GFP
control). GAS1, HMGA2, L1TD1 and PLAC8 expression
required TLX1 DNA-binding activity since introduction
o f  a  D N A  b i n d i n g - d e f i c i e n t  f o r m  o f  T L X 1  c a r r y i n g  a
mutation within the homeodomain (TLX1 N51A) [53]
had minimal if any activity (P < 0.05, TLX1 WT vs TLX1
N51A).
In other recent work, we reported that TLX1 binds the
TLE1 corepressor in an Eh1-dependent manner [49], and
we demonstrated that this interaction is important for
transcriptional activation of two known TLX1 target
genes,  Aldh1a1  and  Fhl1  in NIH3T3 cells [54,55]. We
therefore wished to determine whether any of the
selected TLX1-responsive genes in human T-ALL cells
similarly depend on the Eh1 motif. Notably, we found
that introduction of a TLE binding-deficient mutant of
TLX1 (TLX1 F19E, with a Phe 19 to Glu mutation within
the Eh1 motif) [49] significantly diminished the effect
obtained by TLX1 reconstitution-of-function for GAS1,
PLAC8 and SH3BP5 (P < 0.05, TLX1 WT vs TLX1 F19E)
(Figure 1E). The data thus suggested that DNA-binding
activity and/or TLE interaction are important for TLX1-
mediated transcriptional regulation of the studied TLX1
signature genes.
TLX1 and NOTCH coregulate transcription on a global scale
Toward the identification of transformation-essential
TLX1 targets, we employed an elegant approach recently
described by Land and colleagues, who found that the
gene sets that were coregulated by loss-of-function p53
and Ras activation, but not the targets of either genetic
lesion alone, were enriched in genes required for in vivo
tumorigenic potential [56]. Since activating NOTCH1
mutations are tightly associated with TLX1+ T-ALL [11-
13], we were interested in investigating whether there was
a potential cooperation between NOTCH and TLX1 in
the control of target gene expression underlying leukemic
cell growth, especially in view of the role of TLE proteins
in NOTCH signaling [41-43]. T-ALL-associated muta-
tions in NOTCH1 occur in the extracellular heterodi-
merization (HD) domain and/or the C-terminal PEST
domain of the protein: HD domain mutations increase
the rate of production of the intracellular form of
NOTCH1 and mutations that eliminate the PEST domainRiz et al. Molecular Cancer 2010, 9:181
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increase protein half-life [57]. ALL-SIL cells harbor gain-
of-function NOTCH1 mutations in both the HD domain
and the PEST domain [11]. This NOTCH1 mutant still
requires cleavage by γ-secretase to generate the mature
intracellular form which translocates to the nucleus to
regulate gene transcription. Therefore, we used the γ-
secretase inhibitor (GSI) Compound E [11] to downregu-
late NOTCH pathway signaling in the ALL-SIL cell-
derived populations described above expressing three dif-
ferent levels of TLX1. GSI treatment was with 500 nM
Compound E and RNA was prepared 24 hours posttreat-
ment as described previously [14]. In total, we generated
six different experimental conditions - high, medium or
low TLX1 levels treated with GSI or vehicle control
(DMSO) - and performed expression profiling experi-
ments using cDNA arrays as described above. Principal
Component Analysis indicated that transcription on a
global scale was more profoundly affected by downregu-
lation of TLX1 than by inhibition of NOTCH signaling;
i.e., larger sets of genes were found to be responsive to
changes in TLX1 levels than to GSI treatment (Additional
files 1 and 2). Sets of TLX1-responsive genes derived
from GSI- or DMSO- treated cells overlapped signifi-
cantly as did sets of GSI-responsive genes identified
under the conditions of high or low TLX1 levels (P <
0.0001) (Figure 2A). Using the DAVID gene ontology
classification tool, we performed comparative analysis of
the functions of the genes responsive to NOTCH in the
presence or absence of TLX1 and searched for GO terms
uniquely associated with either of these conditions. The
best DAVID score for TLX1+ conditions was associated
with the GO term "response to external stimulus" (P <
Figure 1 Structure-function analysis of TLX1-mediated transcriptional regulation in ALL-SIL T-ALL cells. (A) TLX1 protein levels inversely cor-
relate with CD55 surface levels. Top, CD55 FACS analysis. Histogram colors indicate: blue, TLX1Low; green, TLX1Med; and red, TLX1High. Bottom, TLX1 
Western blot. TLX1High levels were 6.5× higher and TLX1Med levels were 4.9× higher than TLX1Low levels (P < 0.0001). The difference between the 
TLX1High and TLX1Med levels was statistically significant (P < 0.05). (B) Venn diagram comparing candidate TLX1 target genes derived from two different 
microarray technologies: Affymetrix data have been described [50]; cDNA array targets were selected based on correlation of expression levels with 
TLX1 protein levels (r > 0.9 or < -0.9; 1% FDR; n = 3-4). (C) Hierarchical clustering of genes identified in both profiling experiments. (D) TLX1 levels in 
knockdown and "rescued" ALL-SIL populations: top, Western blot; bottom qRT-PCR. The TLX1 knockdown populations expressing coding regions of 
wild-type or mutant forms of TLX1 are: TLX1 WT, wild-type; TLX1 N51A, DNA binding-deficient mutant; TLX1 F19E, TLE binding-deficient mutant; 
shTLX1 GFP, TLX1 knockdown plus GFP reporter. Total or endogenous TLX1 mRNA levels were determined using primers targeting coding or 3' non-
coding regions of TLX1, respectively. The data is normalized to TLX1 knockdown expressing GFP alone (shTLX1 GFP). (E) TLX1 signature gene expres-
sion in the populations described in D. The data is normalized to TLX1 knockdown expressing GFP alone (P values are indicated in the text and 
Additional file 4; n = 2-3 biological replicates, each comprising 3 technical replicates).
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0.001, representing 8% of the subset under high TLX1
conditions and P < 0.001, representing 6.7% of the subset
under medium TLX1 conditions) whereas the best score
in the absence of TLX1 expression was associated with
the GO term "nervous system development" (P < 0.006,
representing 8.8% of the subset). This data suggested that
expression of TLX1 may influence the functional out-
come of NOTCH pathway activation.
Strikingly, the lists of GSI-responsive genes and TLX1-
responsive genes overlapped very strongly: more than
60% of the GSI-responsive genes were also controlled by
TLX1 (Figure 2A), indicating that a significant fraction of
NOTCH target genes in ALL-SIL cells is coregulated by
TLX1 (P < 0.0001). To quantitatively compare the indi-
vidual contributions of TLX1 and NOTCH in the regula-
tion of common targets, we identified those genes that
are differentially expressed in ALL-SIL cells where TLX1
and NOTCH are "on" versus cells where both factors are
"off" (i.e., GSI-treated TLX1Low cells) (Additional file 3).
As summarized in Figure 2B, downregulation of TLX1
and inhibition of NOTCH affected the regulation of the
vast majority of genes in the same direction. We found
that approximately half of the TLX1-induced genes
showed the highest expression levels in the presence of
NOTCH signaling. Interruption of the transcriptional
output of either factor led to the downregulation of these
genes. Less than 10% showed a much stronger response
to GSI, exhibiting downregulation upon GSI treatment
Figure 2 TLX1 and NOTCH coregulate transcription. (A) ALL-SIL cells were treated for 24 hours with 500 nM Compound E (GSI) and 0.05% DMSO 
as vehicle control and then harvested for microarray analysis. The Venn diagrams indicate a significant overlap between TLX1 targets and GSI-respon-
sive genes (P < 0.0001; data for a 10% FDR is shown). GO terms uniquely associated with the overlapping genes in each pair-wise comparison are 
indicated (see text for details). (B) Hierarchical clustering of known genes showing > 2-fold change under TLX1High versus TLX1Low conditions and a 
FDR < 10%. (C) Confirmation by qRT-PCR of representative coregulated genes. Data is normalized to TLX1Low GSI-treated samples, where both NOTCH 
and TLX1 are downregulated. The average of 3 experiments is shown (P values are indicated in the text where discussed and the P values for all com-
parisons are provided in Additional file 4; n = 3 biological replicates, each comprising 3 technical replicates). (D) TLX1 and NOTCH repress the GAS1 
gene via a TLE corepressor-mediated mechanism. Top, ALL-SIL cells expressing the TX1 shRNA95 or pLKO control vector were transduced with lenti-
viral vectors expressing panTLE shRNAs. Bottom, ALL-SIL cells expressing the pLKO control vector were transduced with lentiviral vectors expressing 
panTLE shRNAs. GSI treatment was for 24 hours. (E) Western blot analysis showing 50% reduced TLE1 levels in ALL-SIL cells expressing panTLE shRNAs 
(P < 0.05).
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and a somewhat more complex response to TLX1 knock-
down. One such example, the NOTCH target gene, DTX1
(Deltex1) [58], was chosen for validation by qRT-PCR
together with 7 TLX1/NOTCH-coinduced genes (CD1B,
HMGA2, L1TD1, OR10R2, PLAC8, SH3BP5, SLC44A1)
and one TLX1/NOTCH-corepressed gene (GAS1). The
qRT-PCR data reported in Figure 2C is presented as rela-
tive expression levels normalized to levels in GSI-treated
TLX1Low cells; thus, a positive value indicates positive
regulation by TLX1 and activated NOTCH. Regulation
by TLX1 in the presence or absence of NOTCH signaling
was demonstrated for all of the putative TLX1/NOTCH-
coinduced genes examined (P < 0.05), and by NOTCH
under conditions of high or low TLX1 expression (P <
0.05, for at least one TLX1 expression condition; see
Additional file 4 for a complete list of P values) (Figure
2C). In support of the generality of these latter results, it
had previously been reported that PLAC8, SH3BP5 and
SLC44A1 were downregulated following NOTCH inhibi-
tion with a different GSI in a different T-ALL-derived cell
line [59] (see also Additional file 5). Regulation of the
NOTCH target gene DTX1 by TLX1 was also confirmed
in this series of experiments (F igure 2C). As expected,
DTX1 showed significantly lower levels of expression fol-
lowing GSI treatment (P < 0.05). Interestingly, under con-
ditions of NOTCH inhibition, DTX1 mRNA levels were
higher in TLX1Low cells than in TLX1High cells (P < 0.05),
reaffirming the complexity of the DTX1  response to
TLX1/NOTCH coregulation suggested by the microarray
data.
We also verified in this series of experiments that GAS1
was repressed by TLX1 (P < 0.001) (Figure 2C). Since the
Eh1 TLE-binding motif mutant of TLX1 (TLX1 F19E)
exhibited markedly reduced GAS1 repressive activity (P <
0.02) (Figure 1E), we decided to directly investigate the
potential contribution of TLE corepressors to the GAS1
repression mechanism. ALL-SIL cells expressing the
TLX1 shRNA95 or pLKO control vector were transduced
with lentiviral vectors expressing panTLE shRNAs. As
seen in Figure 2D, knockdown of TLE resulted in partial
d e r e p r e s s i o n  o f  G A S 1  i n  t h e  p r e s e n c e  o f  T L X 1  ( P  <
0.008). In contrast, no effect was observed under condi-
tions of low TLX1 expression (P = 0.6), indicating that
TLX1 is required for repression of GAS1. The magnitude
of derepression achieved by TLE knockdown (~3-fold)
was much less than that obtained following TLX1 knock-
down (~40-fold), presumably due in part to incomplete
knockdown of TLE. A representative Western blot shown
in Figure 2E indicates that only ~50% downregulation of
TLE1 protein levels was obtained (P < 0.05). In this series
of experiments, GSI treatment also resulted in partial
derepression of GAS1 in the presence of TLX1 (~2-fold,
P < 0.003) (Figure 2D) supporting the data presented in
Figure 2C indicating involvement of NOTCH. Notably,
knockdown of TLE resulted in partial derepression of
GAS1 in the presence of activated NOTCH (~3-fold, P <
0.008) but had no significant additional effect when
NOTCH was inhibited. Collectively, the data for GAS1
supported the hypothesis that TLE corepressors can
serve as common cofactors in the regulation of certain
TLX1/NOTCH-corepressed genes.
To compare the cellular functions regulated by TLX1
and NOTCH together or by either factor separately, we
performed a functional classification of gene sets that
were enriched for NOTCH only-induced genes, TLX1
only-induced genes and TLX1/NOTCH-coinduced
genes. DAVID analysis revealed that all three datasets
were enriched for functional GO terms associated with
developmental processes. In agreement with the well-rec-
ognized survival function of NOTCH in normal and
malignant T cells, we found that the gene set induced by
NOTCH alone was specifically enriched for GO terms
"positive regulation of metabolism" and "apoptosis"
[14,15,27], whereas genes only induced by TLX1 were
enriched for GO terms associated with "chromatin func-
tion and regulation", "proliferation" and "cell-cycle" [60].
Importantly, GO terms associated with "immune system
development" and "oncogenesis" only appeared in the set
of genes regulated by both TLX1 and NOTCH (Figure
2A). Notably, HMGA2  and  PLAC8  were previously
reported to be among the 'cooperation response genes'
identified by loss-of-function p53 and Ras activation as
contributing to the malignant phenotype in colon cancer
[56]. A role of HMGA2 in embryonic growth and devel-
opment has also been described [61-63]. Moreover, the
mouse orthologs of 4 of the other 6 TLX1/NOTCH-coin-
duced signature genes verified by qRT-PCR (L1TD1,
PLAC8,  SH3BP5,  SLC44A1) are downregulated during
differentiation of mouse embryonic stem cells whereas
the TLX1/NOTCH-corepressed target GAS1 is activated
during embryonic stem cell differentiation (GEO profiles
GDS2905 and GDS2906). These observations indicate
that the TLX1/NOTCH leukemic signature shares a com-
mon component with an embryonic stem cell-like tran-
scriptional program [64]. Furthermore, CD1b, the cell
surface marker characteristic of the early cortical thymo-
cyte stage of differentiation arrest associated with the
vast majority of TLX1+ T-ALL cases, was also among the
targets coregulated by TLX1 and NOTCH.
TLX1-mediated augmentation of MYC contributes to T-ALL 
growth regulation
To understand how TLX1 might modulate NOTCH-
dependent transcription, we first examined whether
TLX1 influences intracellular levels of NOTCH1. We
found that neither TLX1 levels nor sorting for CD1/
CD55 affected the levels of activated NOTCH1, whereas,
as expected, GSI treatment markedly decreased intracel-Riz et al. Molecular Cancer 2010, 9:181
http://www.molecular-cancer.com/content/9/1/181
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lular levels of NOTCH1 (Figure 3A). We also found that
expression of constitutively active form of NOTCH1,
ICN1 (encoding the intracellular domain of NOTCH1),
does not substitute for the lack of TLX1 in the growth
regulation of ALL-SIL cells (Figure 3B). However, as
determined by growth competition assay, both factors
synergistically regulated ALL-SIL growth, since GSI
treatment significantly enhanced the differences between
the growth rates of the TLX1-expressing and knockdown
populations (Figure 3C). Together, the data suggested
that TLX1 and NOTCH utilize different but synergistic
mechanisms contributing to the growth of ALL-SIL cells.
We hypothesized that the MYC gene might represent
the master regulatory hub targeted by both oncogenic
lesions because TLX1+ T-ALLs exhibit increased levels of
MYC and MYC target genes [33,60] and NOTCH1
directly activates the MYC  gene at the transcriptional
level in T-ALL [14,15]. We therefore investigated whether
TLX1 and NOTCH coregulate MYC in ALL-SIL cells.
MYC protein levels were found to be lowest in TLX1Low
Figure 3 TLX1 and NOTCH coregulate MYC levels and ALL-SIL growth. (A) ALL-SIL derivatives expressing the indicated levels of TLX1 were treated 
for 24 hours with 500 nM Compound E (GSI, +) and 0.05% DMSO (GSI, -) as vehicle control. Whole cell lysates were analyzed for expression of activated 
NOTCH1 and MYC proteins by Western blotting. A representative blot of 4 biological replicates is shown. (B) Activated NOTCH1 expression does not 
compensate for the lack of TLX1. ALL-SIL cells expressing the TX1 shRNA95 or pLKO.1-CFP control vector were lentivirally transduced to express a con-
stitutively active form of NOTCH1 (ICN1). Cells were seeded at 1 × 105 cells per ml in parallel with mock-transduced controls and counted on days 1 
and 4 by trypan blue staining. (C) Growth competition experiments in the presence or absence of 500 nM Compound E, indicated as GSI and DMSO, 
respectively. ALL-SIL cells expressing TLX1 shRNA95 and CFP or pLKO.1-CFP were mixed with parental ALL-SIL cells in equal proportions. Mixed pop-
ulations were divided, treated with GSI or DMSO control for up to 3 weeks and periodically examined by flow cytometric analysis. (D) TLX1 and NOTCH 
regulation of MYC and HES1 mRNA. (E) TLX1 prevents GSI-induced downregulation of MYC protein and extends MYC half-life. Cells were treated with 
500 nM Compound E or DMSO control for 24 hours, then assayed for MYC protein levels and stability using 50 μg/ml cycloheximide or 40 μM MG132 
treatment for the indicated times.
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cells treated with GSI (Figure 3A). Notably, TLX1 did not
influence MYC mRNA levels under any conditions; e.g.,
MYC  mRNA levels decreased following GSI treatment
regardless of TLX1 expression (P < 0.05, GSI- vs DMSO-
treated cells) although TLX1 prevented GSI-mediated
downregulation of HES1 mRNA (P < 0.05) (Figure 3D).
We asked next if TLX1 expression contributes to the syn-
thesis or stability of the MYC protein. As shown in Figure
3E, TLX1 increased MYC protein levels in the presence
of the MG132 protease inhibitor and, in addition, as seen
from cycloheximide treatment, prolonged MYC protein
half-life. NOTCH also positively contributed to total
MYC protein levels, consistent with previously published
data showing that NOTCH directly activates MYC gene
expression in T-ALL [14,15]. The data thus suggested that
TLX1 contributes to the NOTCH-MYC oncogenic axis at
least in part via augmentation of MYC protein expression
and stability.
Next, we assessed the functional role of TLX1-medi-
ated augmentation of MYC and asked how inhibition of
MYC activity affects the growth of ALL-SIL cells. ALL-
SIL cells were treated with a small-molecule MYC inhibi-
tor, compound 10058-F4 [65,66]. Compound 10058-F4
treatment decreased the growth of ALL-SIL cells to simi-
lar levels regardless of TLX1 expression (Figure 4A), sug-
gesting that augmentation of MYC function is a central
mechanism of TLX1 contribution to ALL-SIL cell
growth. Ectopic expression of wild-type MYC in TLX1Low
ALL-SIL derivatives fully compensated for the knock-
down of endogenous TLX1. On the other hand, an inac-
tive MYC mutant missing an evolutionarily conserved
region called MYC homology box II (MYC ΔC) [67] was
not capable of promoting growth of the cells (Figure 4B,
C), as expected [68]. Interestingly, we found that a large
fraction of TLX1/NOTCH-targeted genes was repre-
sented by potential MYC targets when we compared the
expression profiling data with MYC CHIP-on-chip data
obtained previously for the TLX3+ T-ALL-derived cell
line HPB-ALL [58] (Additional file 5). Accordingly, we
determined that of 8 representative genes coinduced by
TLX1 and NOTCH, 6 were inhibited by 10058-F4 treat-
ment (Table 1). Interestingly, PLAC8  expression was
upregulated by the MYC inhibitor in agreement with pre-
viously published data showing repression of PLAC8 in
response to MYC overexpression [69]. Since we found
that both TLX1 and NOTCH activated PLAC8, the data
suggested that, at least in this case, there is a more com-
plex interplay between the three transcription factors
than simple coactivation.
TLX1/NOTCH coregulation of T-cell developmental genes
The functional classification of the TLX1/NOTCH-
coregulated genes suggested that concerted activity of
these oncogenes may alter T-cell development. We previ-
ously reported that TLX1 downregulation correlates with
a decrease in CD1b surface expression in ALL-SIL cells
and in another TLX1+ T-ALL cell line (K3P) [50]. Here we
investigated whether inhibition of NOTCH contributes
Figure 4 Role of MYC as a downstream component of the TLX1/
NOTCH regulatory network. (A) Chemical inhibition of MYC (10058-
F4 treatment) mimics TLX1 knockdown in ALL-SIL cells expressing 
shRNA93 versus pLKO.1-CFP expressing TLX1+ controls. (B) Expression 
of wild-type but not an inactive MYC mutant (MYC ΔC) compensates 
for the lack of TLX1 expression in ALL-SIL cells treated with GSI. TLX1 
shRNA93 was co-expressed with CFP; MYC constructs were coex-
pressed with RFP. ALL-SIL cells expressing pLKO.1-CFP-TLX1 shRNA93 
were transduced with retroviral vectors coexpressing RFP alone, wild-
type MYC plus RFP or the MYC ΔC mutant plus RFP and sorted for CFP 
and RFP expression. Equal numbers were seeded and counted after 2 
weeks in culture. CFP + RFP, parental ALL-SIL cells coexpressing CFP 
and RFP. (C) Growth competition experiments. The same CFP+RFP+ 
ALL-SIL derivatives as in B were mixed with parental ALL-SIL cells ex-
pressing GFP in equal proportions. Aliquots were periodically analyzed 
by flow cytometry; shown are data 2 weeks after initiation of the exper-
iment. (D) Western blot analysis showing MYC protein levels and the 
corresponding levels of TLX1 for the cell lines studied in B and C.
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Table 1: TLX1/NOTCH signature gene response to MYC 
inhibition in ALL-SIL cells
Gene Fold Downregulation
CD1B 3.6 ± 0.4
HMGA2 2.4 ± 0.3
L1TD1 5.9 ± 0.4
OR10R2 1.9 ± 0.1
PLAC8 0.5 ± 0.1
RAG1 11.1 ± 2.7
SH3BP5 1.2 ± 0.1
SLC44A1 1.5 ± 0.1
Fold downregulation was defined as the ratio of the qRT-PCR 
values obtained for untreated cells (DMSO) versus cells treated 
for 2 days with 50 μM of the MYC inhibitor 10058-F4.Riz et al. Molecular Cancer 2010, 9:181
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to CD1b surface expression as well. First, we character-
ized the surface phenotype of ALL-SIL cells in greater
detail. Although the majority of the cells (~70%) are
CD4+CD8+CD1b+/- (DP-like), we found that ~30% exhibit
a CD4+CD8-CD1b+ ISP-like phenotype and ~2% exhibit a
CD4-CD8+CD1b-  SP-like phenotype. When the
CD4+CD8-CD1b+ ISP-like population was sorted (>90%
purity) and returned to continuous culture for 2 weeks,
the phenotypic heterogeneity remerged with ~55% of the
cells exhibiting a DP-like CD4+CD8+CD1b+/- phenotype
(Figure 5A). Additionally, sorted DP-like populations pro-
duced about 2% SP-like cells (data not shown). Thus, the
observed heterogeneity of the surface phenotype of the
ALL-SIL line resembles a dynamic system of states remi-
niscent of a hierarchical organization of malignant T-ALL
cells [70], with the majority of cells arrested at the early
DP stage typical for TLX1+ T-ALL [32-36]. Downregula-
tion of TLX1 by transduction with an shRNA95-express-
ing vector followed by puromycin selection or an
shRNA93- plus CFP-expressing vector followed by FACS
caused a marked decrease in CD1b levels in both ISP-like
and DP-like populations. In addition, we found that 2
weeks of GSI treatment decreased CD1b surface expres-
sion, predominantly affecting the ISP-like populations;
however, when TLX1 was knocked down, GSI treatment
caused a decrease in the surface expression of CD1b in
both DP- and ISP-like populations. Moreover, the effect
of GSI treatment was irreversible in the TLX1 knock-
down populations since, even when the cells fully recov-
ered 1 month after GSI treatment, CD1b could not be
detected on the cell surface. This is illustrated in Figure
5B, where it can be seen that the ALL-SIL population bal-
ance was shifted toward more mature phenotypes, with
reduced percentages of ISP-like, and increased percent-
ages of DP- and SP-like populations.
To determine whether other developmental genes were
regulated in a similar manner, we searched for genes that
were coregulated with CD1 family members during nor-
mal thymocyte development. RAG1 was identified previ-
ously as a gene whose expression closely resembles the
expression pattern of CD1 [31,32]; specifically, downreg-
ulation of both genes occurs at the DP stage, with RAG1
downregulation being required for the DP to SP transi-
tion [71,72]. We sorted ISP-like and DP-like populations
from ALL-SIL cells with or without TLX1 knockdown
and transient NOTCH inhibition (2 weeks of GSI treat-
ment or DMSO and 1 month recovery). W e examined
CD1B and RAG1 mRNA levels in these populations and
observed a striking concordance in their expression
changes; e.g., temporary inhibition of NOTCH signaling
in TLX1 knockdown populations led to irreversible
repression of CD1B and RAG1 (Figure 5C). In addition,
ectopic reexpression of TLX1 in CD1b- cells failed to
reactivate these genes (data not shown). Thus, we found
that transient downregulation of NOTCH in concert with
TLX1 knockdown is required and sufficient to induce
irreversible repression of CD1B  and  RAG1. Since the
silencing of these genes is an important aspect of the nor-
mal T-cell differentiation program, the data suggest that
TLX1/NOTCH-coregulated maintenance of their expres-
sion exemplifies a mechanism underlying the ALL-SIL
differentiation arrest. Interestingly, downregulation of
TLE caused a significant decrease in the percentage of
CD1b+  cells, suggesting that TLX1-TLE interaction is
involved in the TLX1-imposed differentiation arrest (Fig-
ure 5D).
Discussion
Several lines of evidence indicate that TLX1 functions as
a transcriptional regulator that can either activate or
repress gene expression [49,50,53-55,60,73-76]. The situ-
ation is complicated by the fact that TLX1 may switch its
mode of regulation of the same gene depending on as yet
ill-defined tissue-specific factors that may include the
availability of transcriptional cofactors, the presence or
state of activation of cis-regulatory DNA elements, and/
or the expression levels of the TLX1 protein itself (our
unpublished observations and [54]). Recently, for two of
the best characterized DNA binding-dependent TLX1
targets, Aldh1a1 and Fhl1, we reported that TLX1 acti-
vates transcription via interaction with the transcrip-
tional corepressor TLE [49]. However, the significance of
this observation for TLX1-associated leukemogenesis as
well as the leukemia-specific downstream targets of
TLX1 still remained elusive. In the present work, using a
human cell line derived from a TLX1+ T-ALL patient
sample we have identified several genes that were upreg-
ulated by TLX1 in a DNA binding-dependent manner.
Although statistical significance was only reached for a
subset of genes examined, an intact Eh1 TLE-binding
motif was necessary for maximal effect in all cases with
the exception of L1TD1. Additionally, we identified a
potential direct TLX1 target gene, GAS1, which was
repressed by TLX1 in a classical TLE and DNA binding-
dependent manner [48]. Interestingly, we found that our
attempts to overexpress TLE1 by retroviral-mediated
gene delivery resulted in massive cell death in TLX1
knockdown derivatives but not in parental ALL-SIL cells
(our unpublished observations). Taken together, our data
suggest that TLX1 interaction with TLE may be an inte-
gral component of TLX1 leukemic function (Figure 6). To
explain how TLX1-TLE binding may cause transcrip-
tional activation, we can envisage at least two mecha-
nisms: 1) TLX1-TLE-mediated repression of unknown
intermediary transcriptional repressors (referred to as
the repressor-of-repressor mechanism [77]); and/or 2) ARiz et al. Molecular Cancer 2010, 9:181
http://www.molecular-cancer.com/content/9/1/181
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Figure 5 TLX1 and NOTCH coregulate expression of T-cell developmental genes. (A) FACS analysis of a CD4+CD8-CD1b+ ISP-like subpopulation 
of TLX1+ ALL-SIL cells immediately after sorting (left) and after culture for 2 weeks (right). (B) Transient inhibition of NOTCH and downregulation of 
TLX1 shifts ALL-SIL populations toward a more differentiated phenotype. Flow cytometry-based comparison of TLX1+ ALL-SIL cells expressing CFP and 
TLX1 knockdown cells expressing shRNA93 treated by a pulse of GSI. The pulse of GSI consisted of 2 weeks treatment with 500 nM Compound E fol-
lowed by culture for 1 month. (C) qRT-PCR detection of RAG1 and CD1B in the same cell lines as in B. The data shown is a representative example for 
CD4+CD8+ (DP) and for CD4+ (ISP-like and SP-like) populations. RNA was extracted from the cells 24 hours after sorting (P values for all comparisons 
are provided in Additional file 4; n = 2 biological replicates, each comprising 3 technical replicates). (D) The role of TLE corepressors in TLX1-mediated 
regulation of CD1b surface expression. Flow cytometric analysis of ALL-SIL expressing shRNA targeting TLX1 or panTLE. The percentage of CD1b+ pop-
ulations are shown for CD4+CD8+ (green) and for CD4+ (red) populations of ALL-SIL cells.
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derepression strategy involving competitive sequestra-
tion of TLE from other TLE-dependent transcriptional
repressors. To illustrate the validity of the second mecha-
nism, we previously used a well-established HES1-TLE-
dependent repressor model involving the ASCL1/HASH1
gene and showed that ectopic expression of TLX1 dis-
missed TLE from the ASCL1 promoter, preventing HES1-
mediated ASCL1 repression [49].
The TLE protein family plays a role in a negative loop of
r e g u l a t i o n  o f  N O T C H  a s  w e l l  a s  f a c i l i t a t i n g  N O T C H
repressor function [38,41]. We found that TLX1 coregu-
lated a large proportion of NOTCH-responsive genes. As
w a s  c o n f i r m e d  b y  q R T - P C R ,  a l l  o f  t h e  T L X 1  t a r g e t s
requiring the Eh1 TLE-binding motif for their full activa-
tion were also positively regulated by NOTCH, implicat-
ing TLX1-TLE interaction in the derepression of
NOTCH-induced genes. Downregulation of TLE levels
by pan-TLE targeting shRNA was associated with partial
transcriptional derepression of the GAS1 gene, support-
ing the idea that TLE is directly involved in NOTCH- and
TLX1-mediated corepression of certain genes. The genes
induced by TLX1 in a TLE binding-dependent manner
also responded to reduced TLE levels but the effects were
variable, consistent with multiple indirect modes of TLE
involvement. Also, one of the strongest transcriptional
activation responses to TLX1 and NOTCH, exhibited by
the L1TD1 gene, does not require the Eh1 TLE-binding
motif for maximal effect. However, expression of L1TD1
and most of the other TLX1-NOTCH signature genes
studied were strongly inhibited by the 10058-F4 MYC
inhibitor [65,66]. Since we found that TLX1 expression
enhances MYC protein levels in ALL-SIL cells and that
this is a central facet of TLX1-mediated growth control,
we conclude that augmentation of MYC activity is an
additional and important aspect of TLX1/NOTCH coop-
eration. It was previously appreciated that high levels of
expression of MYC target genes is a characteristic feature
of TLX1+ T-ALLs [33,60]. Thus, our results provide an
explanation for these observations and link TLX1 to the
NOTCH-MYC signaling axis (Figure 6) [14,58]. In retro-
spect, since the majority of NOTCH-induced genes in T-
ALL are also targeted by MYC [58], it is perhaps not sur-
prising to find that virtually all of the TLX1/NOTCH sig-
nature genes that we validated by qRT-PCR negatively
responded to inhibition of MYC by compound 10058-F4
treatment. Another level of complexity has arisen with a
recent publication showing that mammalian MYC and
TLE proteins directly bind in vitro [44]. In that study, the
investigators also reported that TLE antagonized MYC
transcriptional activation of growth-promoting genes in
Drosophila [44]. It is possible therefore that TLX1-medi-
ated modulation of TLE interactions may derepress MYC
target genes as well as NOTCH-responsive genes in T-
ALL cells (Figure 6). Finally, promoter analysis of the
genes whose expression positively correlated with TLX1
expression showed enrichment for NOTCH-responsive
elements (our unpublished observations). Others have
shown that TLX1 interacts with SHARP, a corepressor
protein directly controlling NOTCH target genes via this
element [78,79]. Thus, we speculate that TLX1-SHARP
interaction may be an additional point of intersection
with the NOTCH signaling pathway.
Since GSI targets all NOTCH receptor family mem-
bers, we deliberately avoided specifying throughout
which NOTCH receptor cooperates with TLX1 in ALL-
SIL cells. However, the fact that NOTCH1 is mutated in
these cells [11], considered together with our Western
blot results showing that GSI treatment markedly
decreased intracellular levels of NOTCH1, strongly
implicates activated NOTCH1 in the observed coopera-
tion with TLX1 [11]. It is important to point out, how-
ever, that others have suggested that TLX1 may enhance
NOTCH3 signaling in T-ALL cells, although no informa-
tion regarding protein levels or functional activation of
the NOTCH3 receptor was provided [78].
TLX1-activating mutations in T-ALL are associated
w i t h  a n  e a r l y  c o r t i c a l  p h e n o t y p e ,  s u g g e s t i n g  a  d i r e c t
inhibitory effect preventing the differentiation of thymo-
cytes past this developmental stage [32-36]. In experi-
mental models, we and others have observed that TLX1
Figure 6 Schematic summary of regulatory network controlling 
TLX1/NOTCH signature genes. NOTCH1 activates transcription of 
downstream transcriptional regulators MYC and HES. TLX1 augments 
MYC protein levels. HES represses transcription via interaction with TLE 
[41-43]. TLX1 interacts with TLE to mediate repression and activation of 
transcription [49]. MYC binds TLE directly in vitro [45]. However, it is not 
known whether TLE is required for MYC repressor activity (indicated by 
"?"). We speculate that the genes coregulated by the TLX1/TLE/
NOTCH/MYC network are critical for TLX1/NOTCH transforming func-
tion in T-ALL.
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expression may lead to differentiation arrest of a broad
spectrum of hematopoietic precursors, and that extinc-
tion of TLX1 expression released the block allowing con-
tinuation of the differentiation program in erythroid
precursors conditionally expressing TLX1 [76,80]. More-
over, we recently showed that TLX1 downregulation in
ALL-SIL cells correlates with acquisition of a surface phe-
notype associated with early cortical to late cortical thy-
mocyte development epitomized by downregulation of
CD1 family members, partially recapitulating the T-cell
differentiation program [50]. Here, we have extended the
latter studies to demonstrate that the CD1B marker of
e a r l y  c o r t i c a l  t h y m o c y t e s  i s  c o r e g u l a t e d  b y  T L X 1  a n d
NOTCH concomitant with maintenance of RAG1 expres-
sion. Downregulation of RAG1 in cortical thymocytes is
one of the earliest signs of positive selection during nor-
mal thymocyte development [71,72]. In this context, we
found that downregulation of TLX1 and NOTCH in
ALL-SIL cells leads to irreversible repression of the CD1B
and  RAG1  genes, since reexpression of TLX1 in the
sorted CD1b- cells or resumption of NOTCH signaling
was not sufficient to reactivate their expression. There-
fore, the data is consistent with a role of TLX1/NOTCH
cooperation in preventing the differentiation-pro-
grammed repression of the CD1B and RAG1 genes rather
than one involving transcriptional activation of CD1 and
RAG family members. In addition, we found that CD1B
and RAG1 were negatively regulated by MYC inhibition.
Collectively, these findings implicate the TLX1/NOTCH-
MYC network in maintaining the CD1+ early cortical
stage of TLX1+ T-ALL cells.
A major motivation for these studies was to identify
potential therapeutic targets that are critical to the malig-
nant phenotype in T-ALL. The study design was modeled
after that of Land and colleagues who demonstrated in
experimental models of murine and human colon cancer
that malignancy was strongly correlated with a class of
genes they referred to as 'cooperation response genes'
which were synergistically regulated by cooperating
oncogenic mutations [56]. Based on their observations
that the malignant state depended on a similar set of
genes in both experimental systems, the investigators
suggested that cooperation response genes may broadly
contribute to the generation and maintenance of the can-
cer cell phenotype in a variety of contexts. It is notable
therefore that HMGA2 and PLAC8 were among the genes
that we identified. HMGA2 belongs to the high mobility
group AT-hook family of architectural nuclear factors
involved in chromatin remodeling and gene transcrip-
tion. It is predominantly expressed during normal embry-
onic development, but has been implicated as
contributing to the transformed phenotype and poor
prognosis of a wide variety of human neoplasms [81,82]
including hematologic malignancies [83-85]. The PLAC8
gene encodes a cysteine-rich protein of unknown func-
tion which has been suggested to be involved in cell sur-
vival and transformation [69]. It was the top-ranked
cooperation response gene identified by Land and col-
leagues whose perturbation in both murine and human
colon cancer cells inhibited tumor formation in mice [56].
Increased expression of PLAC8  has been reported in
putative cancer stem cells in liver and breast cancer cell
lines [86,87]. More intriguing, the PLAC8  gene was
among the gene signatures predictive of relapse in ALL
patients in two recent studies [88,89]. In particular, in a
study of 50 T-ALL patients, PLAC8 was one of 5 genes
that accurately predicted clinical outcome [89]. The accu-
mulated data thus support the idea that HMGA2  and
PLAC8 may play a central role in the malignant pheno-
type of a broad spectrum of cancers of diverse origins.
Conclusions
Despite the fact that the oncogenic function of TLX1 and
NOTCH1 is well established in T-ALL, the mechanistic
basis of their cooperation remained to be clarified. Our
data suggest that in the process of leukemic transforma-
tion TLX1 enhances NOTCH signaling output and that
both factors contribute to T-ALL cell survival and differ-
entiation arrest. We believe that a search for the common
gates targeted by these cooperating genetic lesions will
help to better understand the nature of the disease and
lead to the development of more effective and less toxic
therapeutic regimens. The TLX1/NOTCH 'cooperation
response genes' listed in Table 1, especially HMGA2 and
PLAC8, represent attractive candidates for further studies
along these lines.
Methods
shRNA knockdown and gene transfer experiments
ALL-SIL cells were cultured as previously described [60].
TLX1 shRNA knockdown analyses were performed as
previously reported [50] with the following modifica-
tions. TLX1 shRNAs were obtained from the MISSION™
TRC TLX1 shRNA target set (Cat. No. NM_005521,
Sigma-Aldrich) cloned into the pLKO.1-puro lentiviral
vector backbone [90]: TRCN0000014993 (designated
TLX1 shRNA93) targets sequences within the TLX1 3'
noncoding region and TRCN0000014995 (designated
TLX1 shRNA95) targets the TLX1 coding region. The
pLKO.1-CFP-TLX1 shRNA93, pLKO.1-CFP-TLX1
shRNA95 and pLKO.1-CFP lentiviral vectors were cre-
ated by replacing the puromycin resistance genes in the
corresponding pLKO.1-puro plasmids with the enhanced
cyan fluorescent protein (CFP) gene from the MCIN ret-
roviral vector [91,92]. The resulting pLKO.1-CFP lentivi-
ral vector backbone was also used to generate pan TLE
knockdown ALL-SIL cells. The TLE shRNAs were based
on an shRNA (TLE1/4si2) previously shown to efficientlyRiz et al. Molecular Cancer 2010, 9:181
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knock down TLE1 and  TLE4 in human leukemia cells
[47]. The TLE shRNA target sequences were as follows:
shRNA1/4, GGTCTGCTTCTCATGCTGCAG, which
targets sequences in common to both TLE1 and TLE4;
shRNA2, GGTTTGCTTCTCCTGCTGCAG, and
shRNA3, AGTCTGCTTCTCCTGCTGCAG, which tar-
get the corresponding regions in TLE2 and TLE3. Dou-
ble-stranded DNAs including the 21-mer TLE shRNA
sequences [90] were ligated into the AgeI-EcoRI sites of
pLKO.1-CFP. The TLX1 wild-type, and the TLX1 N51A
and TLX1 F19E mutant coding regions were previously
described [49,53]; these were inserted into the MSCV-
GW retroviral vector that coexpresses the enhanced
green fluorescent protein (GFP) gene [93]. MYC retrovi-
ral expression vectors were constructed by cloning the
MYC wild-type and MYC ΔC (amino acids 127-189
deleted) mutant coding regions [67] (provided by Dr. Wil-
liam Tansey, Cold Spring Harbor Laboratory, Cold Spring
Harbor, NY) into the MSCV-RW retroviral vector in
which the GFP gene in MSCV-GW was replaced with the
DsRed-Express2 red fluorescent protein (RFP) gene [94]
(provided by Dr. Benjamin Glick, The University of Chi-
cago, Chicago, IL). A lentiviral vector that coexpresses a
constitutively active form of NOTCH1  encoding the
intracellular domain of the human NOTCH1 receptor
(ICN1; codons 1770-2555) (provided by Dr. Warren Pear,
University of Pennsylvania School of Medicine, Philadel-
phia, PA) [95] and RFP was previously described [49].
Vesicular stomatitis virus (VSV)-G glycoprotein-
pseudotyped lentiviral vector particles were produced by
transiently transfecting the lentiviral vector plasmids (15
μg), the packaging plasmid pCMVΔR8.91 (10 μg) and the
VSV-G protein envelope plasmid pMD.G (5 μg) into sub-
confluent human embryonic kidney 293T cells by the cal-
cium phosphate precipitation method [96], and were
used to transduce ALL-SIL cells as previously described
[50]. Amphotropic retroviral particles were similarly pro-
duced by transiently transfecting 293T cells with retrovi-
ral vector plasmids (10 μg) and the pCL-Ampho
packaging construct (10 μg), and were used to transduce
ALL-SIL cells as previously described [60].
Fluorescence activated cell sorting and analysis
Vector-transduced ALL-SIL cells expressing CFP, GFP
and/or RFP were sorted on a FACSAria instrument (BD
Biosciences) equipped with 407-nm solid state, 488-nm
solid state and 633-nm HeNe lasers [91,92]. Where indi-
cated, the cells were stained with anti-CD1b-Alexa Fluor
647 and anti-CD55-PE monoclonal antibodies prior to
sorting. Other monoclonal antibodies included, anti-
CD4-FITC, anti-CD4-PE, anti-CD8-FITC and anti-CD8-
PE (all purchased from eBioscience). Cell staining was
carried out with saturating concentrations of reagents as
described [97] and flow cytometry data was analyzed
using FACSDiva software (BD Biosciences).
Cell growth assays
ALL-SIL cell populations expressing fluorescent protein
reporters (CFP, GFP or RFP) were mixed in equal propor-
tions and periodically analyzed by flow cytometric moni-
toring. In some experiments, cell growth was measured
using the alamarBlue cell viability and proliferation
reagent (Invitrogen) as previously described [50]. Where
indicated, ALL-SIL cell populations were treated with the
GSI, Compound E, at 500 nM for 24 hours [14] or 2
weeks [11], or with the MYC chemical inhibitor 10058-F4
(both from Calbiochem, EMD Chemicals) at the indi-
cated concentrations as previously described [65,66].
MG132 and cycloheximide were from Sigma-Aldrich.
Mock-treated cultures contained 0.05% dimethylsulfox-
ide (DMSO) as solvent vehicle control.
Quantitative real-time RT-PCR validation and analysis of 
genes
Real-time qRT-PCR was performed using the Power
SYBR Green reagent (Applied Biosystems) on an ABI
Prism 7000 Sequence Detection System as previously
described [76,98]. Primers: TLX1 coding (CATCGAC-
CAGATCCTCAACA, CAGCCAAGGCCGTATTCTC);
TLX1 3' noncoding (GTCACTGTCCCTCCTGGTGT,
GCCTGATCGTAAGGTCCAAA); L1TD1 (ACGCCAG-
GGTGACTACAAAC, GCTGTCCATCCTTCTGGG
TA); OR10R2 (CTTTCTGTGGCCAGGACAAT, AAC-
CCATCACACCCAATAGC); HMGA2 (ACTTCAGC-
CCAGGGACAAC, CTTCCCCTGGGTCTCTTAGG);
DTX1 (GCTAATTGTCTTCGGCCAAC, GCTGGCA
TCCCTTTAAATCTT); CD1B (GCTCCTTTTGCTAT-
GCCTTG, TATTGCGAATGGGAGAGGAG); RAG1 (T
GTTTAATGGCTTCCAAGAGC, ACACAGGTCCCCT
GAATCAA); SH3BP5 (GATGCGGTGTTGGTGCTG,
AGAAATGGCATCAGGCTCAG); SLC44A1 (TCAAA
TGCTTGCTATACAATCTGA, CGTAGAACTCTGGA-
TACTCAATGAA); PLAC8 (GGAGAGCCATGCG-
TACTTTC, CAAGCTGAAGAGGTGTCTGCT); GAS1
(CGGAGCTTGACTTCTTGGAC, CGTCCTGAACA
CTGCAGCTA). qRT-PCR controls, MAPK1, PGK1 and
POLR2A, were selected based on the cDNA hybridiza-
tion data and confirmed not to show any changes in
expression under the experimental conditions studied.
Primers: MAPK1 (CCAGATCCTCAGAGGGTTAAAA,
ATCACAGGTGGTGTTGAGCA); POLR2A (AAGATC-
CTTCCTTGCCTGTG, GCTTTGTTCTTCCCGAG-
GAT) and PGK1 (CAGTTTGGAGCTCCTGGAAG, AG
TTGACTTAGGGGCTGTGC). The data were normal-
ized per MAPK1 expression levels.
Western blotting
Western blotting was performed essentially as previously
described [53,60,76,97]. Antibodies were: TLX1(c-18,
sc880), MYC (c-33, sc-42 and N-262, sc-764),
TLE1(M101, sc-9121) and TLE (C-19, sc-13373) fromRiz et al. Molecular Cancer 2010, 9:181
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Santa Cruz; and anti-Cleaved NOTCH1 (Val1744) from
Cell Signaling.
Microarray gene expression analysis
RNA samples were analyzed with a cDNA microarray
(TIGR 40 K microarray) as previously described [51]. In
brief, total RNA was prepared using Trizol reagent (Invit-
rogen) and the RNeasy mini kit (QIAGEN) as per the
manufacturers' instructions. Expression analysis of ALL-
SIL cells for a particular TLX1 level was derived from
three to four independent GSI and DMSO control treat-
ments. For statistical analysis, a biological replicate
hybridization experiment was defined as an independent
treatment. A hybridization experiment consisted of Cy5-
labeled cDNA that was reverse transcribed from 15 μg of
total RNA and cohybridized with Cy3-labeled cDNA syn-
thesized from an equal amount of the Stratagene Univer-
sal Human Reference RNA, as described [99,100].
Hybridizations were performed for 18-24 hours at 42°C
followed by washing in decreasing concentrations of SSC
at room temperature and spun dry. Microarray platform,
image scanning, fluorescence intensity measurements,
normalization across replicate experiments, experimental
noise determination, cluster analysis and candidate signa-
t u r e  g e n e  i d e n t i f i c a t i o n  w e r e  p e r f o r m e d  a s  p r e v i o u s l y
described [101-104].
Statistical analysis
Unless noted otherwise, the Student's unpaired t test was
used to compare differences between indicated groups. A
P value < 0.05 was considered significant.
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